Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism

Clinical Pharmacology and Therapeutics

Volumn 61, Issue 5, 1997, Pages 509-517

  Okumura, Katsuhiko ^a   Kita, Tomoko ^a   Chikazawa, Shinji ^a   Komada, Fusao ^a   Iwakawa, Seigo ^a,b   Tanigawara, Yusuke ^a  

^a KOBE UNIVERSITY   (Japan)

^b KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACECAINIDE; ACYLTRANSFERASE; PROCAINAMIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG ACETYLATION; DRUG URINE LEVEL; ENZYME POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; POINT MUTATION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TABLET;

ACECAINIDE; ACETYLATION; ADULT; AGED; ARYLAMINE N-ACETYLTRANSFERASE; BASE SEQUENCE; DNA; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; JAPAN; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PLATELET AGGREGATION INHIBITORS; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROCAINAMIDE;

EID: 0030903835     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90131-4     Document Type: Article

References (39)

1. Vatsis KP, Weber WW. Human N-acetyltransferases. In: Kauffman FC, editor. Conjugation-deconjugation reactions in drug metabolism and toxicity. Berlin: Springer-Verlag Press, 1994;112:109-30.
2. Evans DAP. N-Acetyltransferase. Pharmacol Ther 1989;42:157-234.
3. Evans DAP. N-Acetyltransferase. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992;95-178.
4. Ohsako S, Deguchi T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J Biol Chem 1990;265:4630-4.
5. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990;9:193-203.
6. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 1991;39:184-91.
7. Evans DAP, White TA. Human acetylation polymorphism. J Lab Clin Med 1964;63:394-403.
8. Sunahara S, Urano M, Ogawa M. Genetical and geographic studies on isoniazid inactivation. Science 1961;134:1530-1.
9. Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem 1990;265:12757-60.
10. Vatsis KP, Martell KJ, Weber WW. Diverse point mutations in the human gene for polymorphic N-aceryltransferase. Proc Natl Acad Sci USA 1991;88: 6333-7.
11. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in human. Proc Natl Acad Sci USA 1991;88:5237-41.
12. Ebisawa T, Deguchi T. Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases. Biochem Biophys Res Commun 1991;177:1252-7.
13. Mashimo M, Suzuki T, Abe M, Deguchi T. Molecular genotyping of N-acetylation polymorphism to predict phenotype. Hum Genet 1992;90:139-43.
14. Deguchi T. Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J Biol Chem 1992;267:18140-7.
15. Hickman D, Risch A, Camilleri JP, Sim E. Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics 1992;2:217-26.
16. Abe M, Deguchi T, Suzuki T. The structure and characteristics of a fourth allele of polymorphic N-acetyltransferase gene found in the Japanese population. Biochem Biophys Res Commun 1993;191:811-6.
17. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DAP, Grant DM, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1-17.
18. Lin HJ, Han CY, Lin BK, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am J Hum Genet 1993;52:827-34.
19. Reidenberg MM, Drayer DE, Levy M, Warner H. Polymorphic acetylation of procainamide in man. Clin Pharmacol Ther 1975;17:722-30.
20. Woosley RL, Drayer DE, Reidenberg MM, Nies AS, Carr K, Oates JA. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 1978;298:1157-9.
21. Jiang X, Khursigara G, Rubin RL. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 1994;266:810-3.
22. Kinoshita M, Seno T, Shin S, Aono T. Polymorphic genotypes of enzymes involved in carcinogen metabolism as risk factors for the development of human cervical cancer. Jpn J Clin Chem 1994;23:195-202.
23. Wang L, Hirayasu K, Ishizawa M, Kobayashi Y. Purification of genomic DNA from human whole blood by isopropanol-fractionation with concentrated NaI and SDS. Nucleic Acids Res 1994;22:1774-5.
24. Buffone GJ, Darlington GJ. Isolation of DNA from biological specimens without extraction with phenol. Clin Chem 1985;31:164-5.
25. Hickman D, Sim E. N-Acetyltransferase polymorphism: Comparison of phenotype and genotype in humans. Biochem Pharmacol 1991;42:1007-14.
26. Guengerich FP. Metabolic activation of carcinogens. Pharmacol Ther 1992;54:17-61.
27. Ilett KF, David BM, Detchon P, Castleden WM, Kwa R. Acetylation phenotype in colorectal carcinoma. Cancer Res 1987;47:1466-9.
28. Mommsen S, Aagaard J. Susceptibility in urinary bladder cancer: Acetyltransferase phenotypes and related risk factors. Cancer Lett 1986;32:199-205.
29. Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, et al. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 1994;369:154-6.
30. Agundez JAG, Ladero JM, Olivera M, Abildua R, Roman JM, Benitez J. Genetic analysis of the arylamine N-acetyltransferase polymorphism in breast cancer patients. Oncology 1995;52:7-11.
31. Graf T, Broly F, Hoffmann F, Probst M, Meyer UA, Howald H. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur J Clin Pharmacol 1992;43:399-403.
32. Abe M, Suzuki T, Deguchi T. An improved method for genotyping of N-acetyltransferase polymorphism by polymerase chain reaction. Jpn J Hum Genet 1993; 38:163-8.
33. Yokoi T, Sawada M, Kamataki T. Polymorphic drug metabolism: Studies with recombinant Chinese hamster cells and analyses in human populations. Pharmacogenetics 1995;5:S65-9.
34. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995;57:581-92.
35. Lima JJ, Conti DR, Goldfarb AL, Tilstone WJ, Golden LH, Jusko WJ. Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype. J Pharmacokinet Biopharm 1979;7:69-85.
36. Dutcher JS, Strong JM, Lucas SV, Lee WK, Atkinson AJ Jr. Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology. Clin Pharmacol Ther 1977;22:447-57.
37. Mark LC, Kayden HJ, Steele JM, Cooper JR, Berlin I, Rovenstine EA, et al. The physiological disposition and cardiac effects of procainamide. J Pharmacol Exp Ther 1951;102:5-15.
38. Gibson TP, Atkinson AJ Jr, Matusik E, Nelson LD, Briggs WA. Kinetics of procainamide and N-acetylprocainamide in renal failure. Kidney Int 1977; 12:422-9.
39. Grasela TH, Sheiner LB. Population pharmacokinetics of procainamide from routine clinical data. Clin Pharmacokinet 1984;9:545-54.